Abstract
Parkinson disease (PD) is an already prevalent neurodegenerative disease that is poised to at least double over the next 25 years. Although best known for its characteristic movement disorder, PD is now appreciated commonly to cause cognitive impairment, including dementia, and behavioral changes. Dementia in patients with PD is consequential and has been associated with reduced quality of life, shortened survival, and increased caregiver distress. Here we review clinical presentation and progression, pathological bases, identification of genetic risk factors, development of small molecule biomarkers, and emerging treatments for cognitive impairment in patients with PD.
Keywords: Parkinson disease, cognitive impairment, dementia, Alzheimer disease, Demenita with Lewy bodies
Current Topics in Medicinal Chemistry
Title: Cognitive Impairment and Dementia in Patients with Parkinson Disease
Volume: 9 Issue: 10
Author(s): James B. Leverenz, Joseph F. Quinn, Cyrus Zabetian, Jing Zhang, Kathleen S. Montine and Thomas J. Montine
Affiliation:
Keywords: Parkinson disease, cognitive impairment, dementia, Alzheimer disease, Demenita with Lewy bodies
Abstract: Parkinson disease (PD) is an already prevalent neurodegenerative disease that is poised to at least double over the next 25 years. Although best known for its characteristic movement disorder, PD is now appreciated commonly to cause cognitive impairment, including dementia, and behavioral changes. Dementia in patients with PD is consequential and has been associated with reduced quality of life, shortened survival, and increased caregiver distress. Here we review clinical presentation and progression, pathological bases, identification of genetic risk factors, development of small molecule biomarkers, and emerging treatments for cognitive impairment in patients with PD.
Export Options
About this article
Cite this article as:
Leverenz B. James, Quinn F. Joseph, Zabetian Cyrus, Zhang Jing, Montine S. Kathleen and Montine J. Thomas, Cognitive Impairment and Dementia in Patients with Parkinson Disease, Current Topics in Medicinal Chemistry 2009; 9 (10) . https://dx.doi.org/10.2174/156802609789378218
DOI https://dx.doi.org/10.2174/156802609789378218 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
B-factor Analysis and Conformational Rearrangement of Aldose Reductase
Current Proteomics Role of Nanoparticles in Drug Delivery and Regenerative Therapy for Bone Diseases
Current Drug Delivery Inhibition of Protein-protein Interactions in Plasmodium falciparum: Future Drug Targets
Current Pharmaceutical Design Structure-Based β-Secretase (BACE1) Inhibitors
Current Pharmaceutical Design Structure, Activities and Biomedical Applications of Human Butyrylcholinesterase
Protein & Peptide Letters Fecal DNA Genotyping: A Non-invasive Approach to Characterize Mouse Models for Nutrigenomics Cancer Chemoprevention Studies
Current Pharmacogenomics and Personalized Medicine Pathophysiology of Airway Colonization in Critically ill COPD Patient
Current Drug Targets Clozapine and Olanzapine but not Risperidone Impair the Pre-Frontal Striatal System in relation to Egocentric Spatial Orientation in a Y-Maze
Current Neurovascular Research Eph/Ephrin Signalling and Function in Oncogenesis: Lessons from Embryonic Development
Current Cancer Drug Targets Circadian Rhythms, Melatonin and Depression
Current Pharmaceutical Design The Growth Hormone Secretagogue Receptor (Ghs-R)
Current Pharmaceutical Design Implication of Circadian Rhythms and Melatonin in Major Depressive Disorder: The Evidence Base for New Antidepressant Treatment
Current Psychiatry Reviews Characteristics of Insomniacs Having Sleep State Misperception
Neuroscience and Biomedical Engineering (Discontinued) Spinal Muscular Atrophy: Molecular Mechanisms
Current Molecular Medicine Investigation on Risk Factor of Vascular Thrombotic Diseases in Patients with Obstructive Sleep Apnea Hypopnea Syndrome
Vascular Disease Prevention (Discontinued) Scopolamine and Depression: A Role for Muscarinic Antagonism?
CNS & Neurological Disorders - Drug Targets Glutamate Hypothesis of Schizophrenia and Approach for Possible Therapeutic Drugs
Current Medicinal Chemistry - Central Nervous System Agents Impaired Insulin Sensitivity and Secretion in Patients with Alzheimer’s Disease: The Relationship with Other Atherosclerosis Risk Factors
Current Vascular Pharmacology Cingulate Volume Abnormalities in Emerging Psychosis
Current Pharmaceutical Design Current Opinions and Perspectives on the Role of Immune System in the Pathogenesis of Parkinson's Disease
Current Pharmaceutical Design